Current and Future Pharmacologic Complement Inhibitors - 30/05/15
Résumé |
The availability of anticomplement therapies has been a major achievement for medicine in the last decade. Indeed, eculizumab has changed the treatment paradigm of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome and promises to do the same in several other human complement-mediated diseases. Nowadays, a 10-year experience has also taught us that there are some pitfalls that represent a challenge to improve the current anticomplement treatment. Most of these observations come from paroxysmal nocturnal hemoglobinuria, where unmet clinical needs are emerging, triggering the attention of several investigators and pharmaceutical companies.
Le texte complet de cet article est disponible en PDF.Keywords : Eculizumab, Complement therapeutics, PNH, aHUS, C3, C5, Compstatin
Plan
| The author has received research funding from Alexion Pharmaceuticals, Amyndas Pharmaceuticals, Alnylam Pharmaceuticals, Rapharma, and Novartis. He is also consultant for Alnylam Pharmaceuticals and Rapharma and a member of an Advisory Board for Alexion. |
Vol 29 - N° 3
P. 561-582 - juin 2015 Retour au numéro
Article précédent
- Thrombotic Microangiopathy : Focus on Atypical Hemolytic Uremic Syndrome
- C. John Sperati, Alison R. Moliterno
- Index
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?